Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Physical and functional interaction between HCV core protein and the different p73 isoforms

Abstract

Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions. In fact, HCV core protein has been found to modulate the expression of the cyclin-dependent inhibitor p21WAF1/CIP1 and to promote both apoptosis and cell proliferation through its physical interaction with p53. Here, we studied the ability of HCV core to bind the p53-related p73 protein, its isoforms and its deletion mutants. We found that HCV core co-immunoprecipitated with p73 in HepG2 and SAOS-2 cells. Deletion mutational analysis of p73 indicates that the domain involved in HCV core binding is located between amino-acid residues 321–353. We also demonstrate that p73/core interaction results in the nuclear translocation of HCV core protein either in the presence of the p73 α or p73 β tumor-suppressor proteins. In addition, the interaction with HCV core protein prevents p73 α, but not p73 β dependent cell growth arrest in a p53-dependent manner. Our findings demonstrate that HCV core protein may directly influence the various p73 functions, thus playing a role in HCV pathogenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Balint E, Bates S and Vousden KH . (1999). Oncogene, 18, 3923–3929.

  • Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff ZS, Chapman MJ, Myamura T and Brechot C . (1997). Proc. Natl. Acad. Sci. USA, 94, 1200–1205.

  • Basu A, Meyer K, Ray RB and Ray R . (2002). Virology, 298, 53–62.

  • Colombo M . (1999). J. Hepatol., 31(Suppl 1), 25–30.

  • Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C and Levrero M . (2002). Mol. Cell, 9, 175–186.

  • De Francesco R . (1999). J. Hepatol., 31, 47–53.

  • De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annichiarico-Petruzzeli M, Levrero M and Melino G . (1998). J. Exp. Med., 188, 1763–1768.

  • Giambartolomei S, Covone F, Levrero M and Balsano C . (2001). Oncogene, 20, 2606–2610.

  • Hayashi J, Aoki H, Arakawa Y and Hino O . (1999). Intervirology, 42, 205–210.

  • Higashino F, Pipas JM and Shenk T . (1998). Proc. Natl. Acad. Sci. USA, 95, 15683–15687.

  • Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, Kung H and Jeang KT . (2000). EMBO J., 19, 729–740.

  • Jost CA, Marin MC and Kaelin Jr WG . (1997). Nature, 389, 191–194.

  • Kaghad M, Bonnet H, Yang I, Creancier J, Biscan C, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, Me Keon F and Caput D . (1997). Cell, 90, 809–819.

  • Kaida A, Ariumi Y, Ueda Y, Lin JY, Hijikata M, Ikawa S and Shimotono K . (2000). Oncogene, 19, 827–830.

  • Koike K, Tsutsumi T, Fujie H, Shintani Y and Moriya K . (2002). Oncology, 62, 29–37.

  • Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G and Wang JYJ . (1999). Cell Death Differ., 6, 1146–1153.

  • Lu W, Lo S, Chen M, Wu K, Fung YK and Ou J . (1999). Virology, 264, 134–141.

  • Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, Gounon P, Dubuisson J, Faure G, Crainic R and Budkowska A . (2001). J. Virol., 75, 8240–8250.

  • Mamiya N and Worman HJ . (1999). J. Biol. Chem., 274, 15751–15756.

  • Marusawa H, Hijikata M, Chiba T and Shimotono K . (1999). J. Virol., 73, 4713–4720.

  • Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T and Koike K . (1998). Nat. Med., 9, 1065–1067.

  • Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T and Koike K . (1997). J. Gen. Virol., 78, 1527–1531.

  • Otsuka M, Kato N, Lan KH, Yoshida H, Kato J, Goto T, Shiratori Y and Omata M . (2000). J. Biol. Chem., 275, 34122–34130.

  • Park KJ, Choi SH, Lee SY, Hwang SB and Lai MMC . (2002). J. Biol. Chem., 277, 13122–13128.

  • Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M and El-Deiry WS . (1998). Int. J. Oncol., 13, 5–9.

  • Ray RB, Meyer K and Ray R . (1996). Virology, 226, 176–182.

  • Ray RB, Meyer K and Ray R . (2000). Virology, 271, 197–204.

  • Ray RB, Steel R, Meyer K and Ray R . (1998). Gene, 208, 331–336.

  • Reichelt M, Zang KD, Seifart M, Welter C and Ruffing T . (1999). Arch. Virol., 144, 621–626.

  • Serrano M, Lin AW, Mc Currach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.

  • Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.

  • Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR and Lai MM . (2002). Virology, 292, 198–210.

  • Stiewe T, Theseling CC and Putzer BM . (2002). J. Biol. Chem., 277, 14177–14185.

  • Takamatsu M, Fujita T and Hotta H . (2001). Kobe J. Med. Sci., 47, 97–112.

  • Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K and Wittekind C . (1999). J. Natl. Cancer, 79, 164–167.

  • Thompson EB . (1998). Annu. Rev. Physiol., 60, 575–600.

  • Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K and Miyamura T . (2002). Hepatology, 35, 937–946.

  • Uchida M, Hino N, Yamanaka T, Fukushima H, Imanishi T, Uchiyama Y, Kodama T and Doi T . (2002). Hepatol. Res., 22, 297–306.

  • Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M and Costanzo A . (2002). Oncogene, 21, 3796–3803.

  • Wienzek S, Roth J and Dobbelstein M . (2000). J. Virol., 74, 193–202.

  • Yamanaka T, Kodama T and Doi T . (2002). Biochem. Biophys. Res. Commun., 294, 528–534.

  • You L, Chen C, Yeh T, Tsai T, Mai R, Lin C and Lee Y . (1999). J. Virol., 73, 2841–2853.

  • Zemel R, Koren C, Bachmatove L, Avigad S, Kaganovsky E, Okon E, Ben-Ari Z, Brief F, Ben-Yehoyada M, Shaul Y and Tur-kaspa R . (2002). Dig. Dis. Sci., 47, 716–722.

  • Zeng YX and Eiry WS . (1996). Oncogene, 12, 1557–1564.

  • Zhu N, Khoshan A, Schneider R, Matsumoto M, Denner G, Ware C and Lai MMC . (1998). J. Virol., 72, 3691–3697.

Download references

Acknowledgements

This work was supported by a grant from AIRC and Schering-Plough. Anna Alisi was supported by fellowship from Fondazione A Cesalpino.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Clara Balsano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alisi, A., Giambartolomei, S., Cupelli, F. et al. Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 22, 2573–2580 (2003). https://doi.org/10.1038/sj.onc.1206333

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206333

Keywords

This article is cited by

Search

Quick links